# T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

> **NCT06474676** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Soft-tissue Sarcoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy

## Key facts

- **NCT ID:** NCT06474676
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-29
- **Primary completion:** 2030-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06474676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06474676, "T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06474676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*